Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

semaglutide was taken off the shortage list. Mounjaro®, Eli Lilly’s diabetes GLP-1, entered the market in May 2022 and quickly became a competitor to Ozempic®. Zepbound® (the same drug as ...

When Jenni* started using a medication called liraglutide to lose weight, she noticed changes not just in her appetite, but in how she thought about food. Where the smell of hot chips in the deep ...

Nascent research into the link between gut health and brain function and the rise of GLP-1 weight-loss drugs could aid the ... involved – even in an own-brand way – and it spreading into ...

Drug compounding is allowed when drugs are on the FDA's shortage list, or in circumstances when ... FDA's decision to halt compounded versions of GLP-1 drugs. The FDA says state-licensed ...

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish ... include Trade Desk and Deckers Brands. We sell different types ...

The list price for GLP-1 drugs in the United States ranges between ... “When I start these brand name medications, part of my consent process for these meds is a discussion with my patients ...

Nascent research into the link between gut health and brain function and the rise of GLP-1 weight ... behind the brand of fermented, probiotic milk beverages of the same name.